Date: 2012-11-06
Type of information: Private placement
Company: Exonhit (France)
Investors:
Amount: € 4.4 million
Funding type: private placement
Planned used: These funds will partially fund the cash portion of the merger of Exonhit and Ingen Biosciences.
Others: Exonhit has completed a capital increase totaling € 4.4 million through private placement.This program aims to partially fund the cash portion of the merger with InGen BioSciences. The balance of the cash portion, or 3.6 million, will be financed from available cash. Exonhit has conducted emission 5,813,331 shares for an amount of 4,359,998.25 euros through a capital increase with preferential right of subscription in accordance with the 12th resolution approved at the Extraordinary General Meeting of 2 May 2012.
The Placement price was set at 0.75 euros per share. In accordance with the authorization granted by the Extraordinary General Meeting of Shareholders of May 2, 2012, this price represents a discount of 32.7% compared to the weighted average share price of the Company the last 20 sessions trading days preceding the pricing or 1.1143 euros.
The dilution resulting from the capital increase is 17% compared to the 34,491,657 shares currently outstanding. The new shares will be fungible with existing shares. They will be listed on the NYSE Alternext in Paris on the same line as the existing shares under ISIN code FR0004054427. Settlement should occur Nov. 12, 2012.
Therapeutic area:
